PURPOSE: Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during the gestational period (gp-PABC) or in the first postpartum year (pp-PABC). Despite its infrequent occurrence, the incidence of PABC appears to be rising due to the increasing propensity for women to delay childbirth. We have established the first retrospective registry study of PABC in Ireland to examine specific clinicopathological characteristics, treatments, and maternal and foetal outcomes. METHODS: This was a national, multi-site, retrospective observational study, including PABC patients treated in 12 oncology institutions from August 2001 to January 2020. Data extracted included information on patient demographics, tumour biology, staging, treatments, and maternal/foetal outcomes. Survival data for an age-matched breast cancer population over a similar time period was obtained from the National Cancer Registry of Ireland (NCRI). Standard biostatistical methods were used for analyses. RESULTS: We identified 155 patients-71 (46%) were gp-PABC and 84 (54%) were pp-PABC. The median age was 36 years. Forty-four patients (28%) presented with Stage III disease and 25 (16%) had metastatic disease at diagnosis. High rates of triple-negative (25%) and HER2+ (30%) breast cancer were observed. We observed an inferior 5-year overall survival (OS) rate in our PABC cohort compared to an age-matched breast cancer population in both Stage I-III (77.6% vs 90.9%) and Stage IV disease (18% vs 38.3%). There was a low rate (3%) of foetal complications. CONCLUSION: PABC patients may have poorer survival outcomes. Further prospective data are needed to optimise management of these patients.
PURPOSE: Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during the gestational period (gp-PABC) or in the first postpartum year (pp-PABC). Despite its infrequent occurrence, the incidence of PABC appears to be rising due to the increasing propensity for women to delay childbirth. We have established the first retrospective registry study of PABC in Ireland to examine specific clinicopathological characteristics, treatments, and maternal and foetal outcomes. METHODS: This was a national, multi-site, retrospective observational study, including PABCpatients treated in 12 oncology institutions from August 2001 to January 2020. Data extracted included information on patient demographics, tumour biology, staging, treatments, and maternal/foetal outcomes. Survival data for an age-matched breast cancer population over a similar time period was obtained from the National Cancer Registry of Ireland (NCRI). Standard biostatistical methods were used for analyses. RESULTS: We identified 155 patients-71 (46%) were gp-PABC and 84 (54%) were pp-PABC. The median age was 36 years. Forty-four patients (28%) presented with Stage III disease and 25 (16%) had metastatic disease at diagnosis. High rates of triple-negative (25%) and HER2+ (30%) breast cancer were observed. We observed an inferior 5-year overall survival (OS) rate in our PABC cohort compared to an age-matched breast cancer population in both Stage I-III (77.6% vs 90.9%) and Stage IV disease (18% vs 38.3%). There was a low rate (3%) of foetal complications. CONCLUSION:PABCpatients may have poorer survival outcomes. Further prospective data are needed to optimise management of these patients.
Authors: Kristel Van Calsteren; René Verbesselt; Nelleke Ottevanger; Michael Halaska; Liesbeth Heyns; Rieta Van Bree; Ernst de Bruijn; Daniel Chai; Michel Delforge; Lucien Noens; Vincent Renard; Els Witteveen; Lukas Rob; Jan de Hoon; Frédéric Amant Journal: Acta Obstet Gynecol Scand Date: 2010-10 Impact factor: 3.636
Authors: Frédéric Amant; Sarah Deckers; Kristel Van Calsteren; Sibylle Loibl; Michael Halaska; Lieselot Brepoels; Jos Beijnen; Fatima Cardoso; Oreste Gentilini; Lieven Lagae; Olivier Mir; Patrick Neven; Nelleke Ottevanger; Steven Pans; Fedro Peccatori; Roman Rouzier; Hans-Jörg Senn; Henk Struikmans; Marie-Rose Christiaens; David Cameron; Andreas Du Bois Journal: Eur J Cancer Date: 2010-12 Impact factor: 9.162
Authors: Hatem A Azim; Luigi Santoro; William Russell-Edu; George Pentheroudakis; Nicholas Pavlidis; Fedro A Peccatori Journal: Cancer Treat Rev Date: 2012-07-09 Impact factor: 12.111
Authors: R Rouzier; G Werkoff; C Uzan; O Mir; J Gligorov; L Selleret; F Goffinet; F Goldwasser; J M Treluyer; S Uzan; S Delaloge Journal: Ann Oncol Date: 2011-01-17 Impact factor: 32.976
Authors: Frédéric Amant; Gunter von Minckwitz; Sileny N Han; Marijke Bontenbal; Alistair E Ring; Jerzy Giermek; Hans Wildiers; Tanja Fehm; Sabine C Linn; Bettina Schlehe; Patrick Neven; Pieter J Westenend; Volkmar Müller; Kristel Van Calsteren; Brigitte Rack; Valentina Nekljudova; Nadia Harbeck; Michael Untch; Petronella O Witteveen; Kathrin Schwedler; Christoph Thomssen; Ben Van Calster; Sibylle Loibl Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Waqar Haque; Vivek Verma; Sandra Hatch; V Suzanne Klimberg; E Brian Butler; Bin S Teh Journal: Breast Cancer Res Treat Date: 2018-04-24 Impact factor: 4.872
Authors: Sungmin Park; Ji Sung Lee; Jae Sun Yoon; Nam Hyoung Kim; Seho Park; Hyun Jo Youn; Jong Won Lee; Jung Eun Lee; Jihyoun Lee; Ho Hur; Joon Jeong; Kweon-Cheon Kim; Soo Youn Bae Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738